Friday, 29 March, 2024
HomeNews UpdateWarning on hepatitis C medicine risk

Warning on hepatitis C medicine risk

European health regulators have warned on against using Gilead Sciences Inc's and Bristol-Myers Squibb Co's hepatitis C medicines along with amiodarone, a drug used to regulate the heartbeat of people with heart rhythm disorders, reports Reuters Health.

The European Medicines Agency said there is a risk of severe bradycardia, or heart block, when Gilead's drug harvoni or a combination of Gilead's sovaldi and Bristol-Myers' daklinza are used in patients who are also taking amiodarone.

The agency's committee for medicinal products for human use recommended that amiodarone only be used in patients taking these hepatitis C medicines if other anti-arrhythmics cannot be administered.

[link url="http://www.reuters.com/article/2015/04/24/us-ema-warning-hepatitisc-idUSKBN0NF17U20150424"]Full Reuters Health report[/link]
[link url="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002310.jsp&mid=WC0b01ac058004d5c1"]EMA warning[/link]

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.